【XtalPi · Longbridge Wiki】Key Facts and Resource Navigation (Pinned/Co-Updated)

I'm creating a template, but it's unclear whether it can be maintained long-term. There's no established plan or practice for long-term maintenance yet. I just think this approach is meaningful. The implementation of a community co-construction model also needs exploration. I'm posting this long thread first. If you have ideas on how to maintain this "Frontpage," please share them in the comments below. If a final version is agreed upon, I plan to advance this initiative through maintaining an email list. Aiming to reach a clear conclusion by next weekend.

Positioning: A "Frontpage" for investors of $XTALPI(02228.HK), exclusively featuring publicly available and verifiable definitive information (based on company announcements/prospectuses/annual reports).
Co-construction method: Reply with "[Correction/Addition] + Brief description + Official source link/announcement number." Moderators will consolidate these into the main post weekly.
Update frequency: Rolling updates (weekly or ad-hoc for major announcements).
Scope: Avoid discussions on stock prices, valuations, K-lines, etc. Focus on business, technology, milestones, governance, and disclosures.

Table of Contents

Quick Facts (Factsheet)

Business and Technology Stack

Client and Partnership Milestones (Timeline)

Shareholding Structure and Major Shareholders (Dynamic)

Announcements and Disclosure Portal

Frequently Used Links and External Information

FAQ (For Newcomers)

Co-construction List (Pending Updates/Verification)

Update Log

Quick Facts (Factsheet)

Note: This table only includes definitive, verifiable "framework information." In case of discrepancies, the announcements/prospectuses/annual reports shall prevail.

Business and Technology Stack

Methodological Integration: A hybrid R&D engine combining first-principles/quantum mechanics calculations (QM) + machine learning (AI) + high-performance computing + robotic automation, aiming to enhance the throughput and accuracy of candidate molecule design and validation.ir.xtalpi.comXtalPi

Platform Products

ID4Inno™ (End-to-end small molecule discovery): Rapidly constructs "vast chemical spaces" for specific targets, converging to the most promising lead series, and validates through automated experimental closed-loop iterations.XtalPi

XFEP (Free Energy Perturbation/FEP calculations): Enhances prediction accuracy for small molecule affinity and other properties, serving as a key capability in collaborations with major pharmaceutical companies.World Pharmaceutical Frontiers

Automated Laboratories: Scalable and standardized synthesis, characterization, and bioassay capabilities, forming a closed-loop of "AI ↔ Robotics" data integration.XtalPi

Applications: Accelerates key stages from target validation, molecule generation, affinity prediction, ADMET assessment, to synthesis route design (per prospectus/annual report).ir.xtalpi.com

Client and Partnership Milestones (Timeline)

Only includes publicly verifiable information. The community is encouraged to supplement additional partnership events (with sources).

2025-06-29｜Expanded Strategic Collaboration with Pfizer: Jointly develop a higher-throughput prediction platform to cover Pfizer's expanding small molecule chemical space, deploying tools like XFEP (press release/industry media).prnewswire.comfiercebiotech.comWorld Pharmaceutical Frontiers

2023-05-30/06-01｜Collaboration with Eli Lilly: AI + robotics platform for de novo design and delivery of drug candidates, with milestone payments up to $250 million (PRNewswire/official news).prnewswire.comXtalPi

2020–Present｜Collaboration with Signet Therapeutics and others on pioneering projects for novel targets like gastrointestinal cancer (per public news).XtalPi

Suggestions: Organize historical collaborations with Janssen, UCB, A*STAR, Lilly into a "long table" with timestamps and source references for verification and cross-referencing (volunteers welcome).

Shareholding Structure and Major Shareholders (Dynamic)

This section is updated dynamically per announcements; refer to HKEX disclosures/company annual & interim reports.

Disclosed Major Shareholders/Key Holders (Example, for verification)

WSH Family / TMF (Trust Platform), 5Y Capital (formerly Morningside/Sequoia-related platforms, per actual announcements), Tencent, China Life Private Equity, Goldman Sachs, Sequoia China (HongShan-related platforms per disclosures), etc., appeared in 2025 third-party data platforms/disclosures (refer to announcements & DI notices).MarketScreenerInvesting.comdi.hkex.com.hk

Announcements and Disclosure Portal

Company Website · Investor Relations (Financial reports, announcements, roadshow materials, prospectuses, etc.).ir.xtalpi.com

HKEX Disclosures: Prospectuses, periodic reports, placements/share changes, etc. (Bookmark the "Company Search" page).hkexnews.hkwww1.hkexnews.hk

Interim/Annual Reports (English Examples): 2024 Annual Report (2025-04-07 release), 2025 Interim Results, etc.ir.xtalpi.com+1

Frequently Used Links and External Information

Official Website & Technology Page: Company positioning, platforms, and case studies (English).XtalPi+1

News Center: Collaborations, M&A, and ecosystem updates (e.g., expanded Pfizer collaboration; LCC acquisition).XtalPi

Media Coverage: FierceBiotech, WorldPharma, etc., on Pfizer's expanded collaboration.fiercebiotech.comWorld Pharmaceutical Frontiers

FAQ (For Newcomers)

Q1: What does XtalPi do?
A: A "platform company" for drug and materials R&D using AI+QM+automation—providing R&D services/solutions while gradually expanding into joint development/milestone collaborations (see website/annual report).ir.xtalpi.com

Q2: What are its flagship platforms?
A: ID4Inno™ (small molecule discovery), XFEP (FEP calculations), and scalable automated laboratories.XtalPi+1World Pharmaceutical Frontiers

Q3: Any notable "big pharma" collaborations?
A: Publicly verifiable ones include Eli Lilly (2023) and Pfizer (2025 expansion); specifics subject to official announcements/press releases.prnewswire.com+1

Co-construction List (Pending Updates/Verification)

Shareholder Structure Long Table: Compare pre-/post-latest placement shareholder percentages in a "two-column format" (with announcement numbers).

Partnership Long Table: Supplement Janssen/UCB/A*STAR events with dates, themes, and sources.

Technical Whitepapers/Papers: Select high-value entries on methodology/platform validation with links + one-sentence summaries.

Glossary: Define FEP, ID4Inno, ADMET, high-throughput automation in one sentence.

Volunteer Recruitment: 3–4 volunteers to claim the above tasks; reply with "Claim + WeChat/email (DM acceptable)".

Update Log

v2025-09-03: Created Frontpage; added Factsheet, tech stack, partnership milestones, and announcement portal; launched "Co-construction List." (Moderator: @you)

Notes and Acknowledgments

All factual information here includes clickable sources. If discrepancies with official announcements are found, please comment with authoritative links. Revisions will be made within 24–72h.

Thanks to community members for corrections and additions (credits listed here).